Sutro Biopharma Secures $36,500,000 Series C Round

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=4abc323e-00ef-4dcc-abe9-bd2582d6744e&Preview=1
Date
11/17/2010
Company Name
Sutro Biopharma
Mailing Address
310 Utah Ave South San Francisco, CA 94080
Company Description
Sutro Biopharma, Inc. is a biopharmaceutical company that uses its patented OCFS protein synthesis technology to develop next-generation protein therapeutics for the treatment of human disease.
This commercially scalable technology overcomes important limitations associated with mammalian, yeast, and bacterial systems and allows for faster screening and selection of product candidates without the need to develop cell lines.
Website
http://www.sutrobio.com
Transaction Type
Venture Equity
Transaction Amount
$36,500,000
Transaction Round
Series C
Proceeds Purposes
This financing will support the company’s ongoing development of novel biotherapeutics with superior pharmaceutical properties and advance the company’s biochemical protein synthesis platform to meet current Good Manufacturing Practice (cGMP) standards.
M&A Terms
Venture Investor
Skyline Ventures
Venture Investor
Lilly Ventures
Venture Investor
Amgen Ventures
Venture Investor
SV Life Sciences
Venture Investor
Alta Partners